{
    "url_original": "https://www.wsj.com/articles/hedge-funds-suffer-big-losses-on-biotech-rout-11638727155?mod=markets_lead_pos3",
    "url": "hedge-funds-suffer-big-losses-on-biotech-rout-11638727155",
    "title": "Hedge Funds Suffer Big Losses on Biotech Rout",
    "sub_head": "Some hedge funds have logged losses well into double-digit percentages as regulatory concerns and other issues have buffeted the biotech sector",
    "category_1": "Hedge Funds",
    "image_1_url": "https://images.wsj.net/im-446507?width=860&height=573",
    "image_1": "im-446507.jpg",
    "time": "2021-12-05 12:59:00",
    "body": "Biotech stocks have fallen to earth with a thud in 2021 after soaring last year amid excitement over the development of Covid-19 vaccines, dealing big losses to some hedge funds.<br />The sector is being buffeted by concerns Congress will move to put a lid on drug pricing and a surfeit of early-stage biotech shares as the IPO market booms."
}